Determining the model for end-stage liver disease with better accuracy: Neutralizing the international normalized ratio pitfalls
β Scribed by Richard A. Marlar
- Publisher
- John Wiley and Sons
- Year
- 2007
- Tongue
- English
- Weight
- 48 KB
- Volume
- 46
- Category
- Article
- ISSN
- 0270-9139
No coin nor oath required. For personal study only.
π SIMILAR VOLUMES
The model for end-stage liver disease (MELD) has been a prevailing system to prioritize cirrhotic patients awaiting liver transplantation. An "exceptional" MELD score of 20 and 24 points is assigned for stage T1 and T2 patients with small hepatocellular carcinoma (HCC), respectively. However, this s
## Abstract ## BACKGROUND The Japan Integrated Scoring (JIS) system was revealed as a better model for outcome prediction compared with the Cancer of Liver Italian Program system for hepatocellular carcinoma (HCC), and the Model for EndβStage Liver Disease (MELD) was better as a prognostic predict